Nevertheless, lung cancer patients treated with osimertinib eventually develop acquired resistance, which is characterized by different mechanisms, either according to EGFR-dependent or EGFR-independent pathways [11,16,17,18]. This evidence concerns the gene EGFR and lung cancer.